Peptides derived from lengsin (lgsn), complexes comprising such peptides bound to mhc molecules

ABSTRACT

The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

This application is a divisional of co-pending U.S. application Ser. No.15/777,621, filed May 18, 2018, which is the National Stage ofInternational Application No. PCT/GB2016/053659, filed Nov. 23, 2016,which claims the benefit of and priority to Great Britain PatentApplication Serial No. 1520589.1, filed on Nov. 23, 2015, the contentsof which are incorporated by reference in their entirety.

The present invention relates to novel peptides derived from Lengsin(LGSN), complexes comprising such peptides bound to recombinant MHCmolecules, and cells presenting said peptide in complex with MHCmolecules. Also provided by the present invention are binding moietiesthat bind to the peptides and/or complexes of the invention. Suchmoieties are useful for the development of immunotherapeutic reagentsfor the treatment of diseases such as cancer.

T cells are a key part of the cellular arm of the immune system. Theyspecifically recognise peptide fragments that are derived fromintracellular proteins and presented in complex with MajorHistocompatibility Complex (MHC) molecules on the surface of antigenpresenting cells (APCs). In humans, MHC molecules are known as humanleukocyte antigens (HLA), and both terms are used synonymously herein.MHC molecules have a binding groove in which the peptide fragments bind.Recognition of particular peptide-MHC antigens is mediated by acorresponding T cell receptor (TCR). Tumour cells express various tumourassociated antigens (TAA) and peptides derived from these antigens maybe displayed on the tumour cell surface. Detection of a MHC classI-presented TAA-derived peptide by a CD8+ T cell bearing thecorresponding T cell receptor, leads to targeted killing of the tumourcell. However, as a consequence of the selection processes which occurduring T cell maturation in the thymus, there is a scarcity of T cells(and TCRs) in the circulating repertoire, which recognise TAA-derivedpeptides with a sufficiently high level of affinity. Therefore tumourcells often escape detection.

The identification of particular TAA-derived peptides presented by MHCmolecules on tumour cells enables the development of novelimmunotherapeutic reagents designed to specifically target and destroysaid tumour cells. Such reagents may be moieties that bind to theTAA-derived peptide and/or complexes of peptide and MHC and theytypically function by inducing a T cell response. For example, suchreagents may be based, exclusively, or in part, on T cells, or T cellreceptors (TCRs), or antibodies. The identification of suitable TAAs fortherapeutic targeting requires careful consideration in order tomitigate off-tumour on-target toxicity in a clinical setting. TAAs thatare suitable as targets for immunotherapeutic intervention should show asufficient difference in expression levels between tumour tissue andnormal, healthy tissues; in other words there should be a suitabletherapeutic window, which will enable targeting of tumour tissue andminimise targeting healthy tissues. Ideally TAAs are highly expressed intumour tissue and have limited or no expression in normal healthytissue. Typically, a person skilled in the art would use proteinexpression data to identify whether a therapeutic window exists for agiven TAA. Higher protein expression being indicative of higher levelsof peptide-MHC presented peptide on the cell surface. The inventors ofthe present application have found that differences in RNA expression,rather than protein expression is a more reliable indicator of pMHClevels and consequently the therapeutic window.

It is therefore desirable to provide peptides derived from TAAs with asuitable therapeutic window, based on RNA expression, MHC complexesthereof and binding moieties that can be used for the development of newcancer therapies. Furthermore, it is desirable that said peptides arenot identical to, or highly similar to, any other MHC restrictedpeptide, derived from an alternative protein(s), and presented by MHC onthe surface of non-cancerous cells. The existence of such peptide mimicsincrease the risk of in vivo toxicity for targeted cancer therapies.

In silico algorithms, such as SYFPETHEI (Rammensee, et al.,Immunogenetics. 1999 November; 50(3-4):213-9 (access via syfpeithi.de)and BIMAS (Parker, et al., J. Immunol. 1994 Jan. 1; 152(1):163-75(access via www-bimas.cit.nih.gov/molbio/hla_bind/) are available topredict the amino acid sequences of MHC-presented peptides derived fromproteins. However, these methods are known to generate a high proportionof false positives (since they simply define the likelihood of a givenpeptide being able to bind a given MHC and do not account forintracellular processing). Therefore, it is not possible to accuratelypredict whether a given peptide-MHC is actually presented by tumourcells. Direct experimental data is typically required.

LGSN (also known as lengsin or glutamate-ammonia ligasedomain-containing protein 1 or lens glutamine synthase-like and havingUniprot accession number Q5TDP6) is a ligase involved in terminaldifferentiation in the lens. LGSN has been associated with cancer(Nakatsugawa et al. Cancer Sci. 2009 August; 100(8):1485-93). LGSN is anideal target for immunotherapeutic applications. The inventors havefound that LGSN has a particularly suitable therapeutic window based onRNA expression. The inventors have found novel peptides derived fromLGSN that are presented on the cell surface in complex with MHC. Thesepeptides are particularly useful for the development of reagents thatcan targets cells expressing LGSN and for the treatment of cancers,including non small cell lung cancer (adenocarcinoma).

In a first aspect, the invention provides a peptide comprising,consisting essentially of, or consisting of

-   -   (a) the amino acid sequence of any one of SEQ ID NOS: 1-3, or    -   (b) the amino acid sequence of any one of SEQ ID NOs: 1-3 with        the exception of 1, 2 or 3 amino acid substitutions, and/or 1, 2        or 3 amino acid insertions, and/or 1, 2 or 3 amino acid        deletions,

wherein the peptide forms a complex with a Major HistocompatibilityComplex (MHC) molecule.

The inventors have found that peptides of the invention are presented byMHC on the surface of tumour cells. Accordingly, the peptides of theinvention, as well as moieties that bind the peptide-MHC complexes, canbe used to develop therapeutic reagents.

SEQ ID NO Amino acid sequence 1 ALGETFIRYFV 2 LSCLMAPSV 3 QILTPPQL

In a preferred embodiment the peptides have the following sequences:

1 ALGETFIRYFV

As is known in the art the ability of a peptide to form an immunogeniccomplex with a given MHC type, and thus activate T cells, is determinedby the stability and affinity of the peptide-MHC interaction (van derBurg et al. J Immunol. 1996 May 1; 156(9):3308-14). The skilled personcan, for example, determine whether or not a given polypeptide forms acomplex with an MHC molecule by determining whether the MHC can berefoldead in the presence of the polypeptide using the process set outin Example 2. If the polypeptide does not form a complex with MHC thenMHC will not refold. Refolding is commonly confirmed using an antibodythat recognises MHC in a folded state only. Further details can be foundin Garboczi et al., Proc Natl Acad Sci USA. 1992 Apr. 15; 89(8):3429-33.Alternatively, the skilled person may determine the ability of a peptideto stabilise MHC on the surface of TAP-deficient cell lines such as T2cells, or other biophysical methods to determine interaction parameters(Harndahl et al. J Biomol Screen. 2009 February; 14(2):173-80).

Preferably, peptides of the invention are from about 8 to about 16 aminoacids in length, and are most preferably 8, 9, or 10 or 11 amino acidsin length, most preferably 11 amino acids in length.

The peptides of the invention may consist or consist essentially of theamino acids sequences provided in SEQ ID NOs: 1-3.

The amino acid residues comprising the peptides of the invention may bechemically modified. Examples of chemical modifications include thosecorresponding to post translational modifications for examplephosphorylation, acetylation and deamidation (Engelhard et al., CurrOpin Immunol. 2006 February; 18(1):92-7). Chemical modifications may notcorrespond to those that may be present in vivo. For example, the N or Cterminal ends of the peptide may be modified improve the stability,bioavailability and or affinity of the peptides (see for example,Brinckerhoff et al Int J Cancer. 1999 Oct. 29; 83(3):326-34). Furtherexamples of non-natural modifications include incorporation ofnon-encoded α-amino acids, photoreactive cross-linking amino acids,N-methylated amino acids, and β-amino acids, backbone reduction,retroinversion by using d-amino acids, N-terminal methylation andC-terminal amidation and pegylation.

Amino acid substitution means that an amino acid residue is substitutedfor a replacement amino acid residue at the same position. Insertedamino acid residues may be inserted at any position and may be insertedsuch that some or all of the inserted amino acid residues areimmediately adjacent one another or may be inserted such that none ofthe inserted amino acid residues is immediately adjacent anotherinserted amino acid residue. One, two or three amino acids may bedeleted from the sequence of SEQ ID NOs: 1-3. Each deletion can takeplace at any position of SEQ ID NOs: 1-3.

In some embodiments, the polypeptide of the invention may comprise one,two or three additional amino acids at the C-terminal end and/or at theN-terminal end of the sequence of SEQ ID NOs: 1-3. A polypeptide of theinvention may comprise the amino acid sequence of SEQ ID NOs: 1-3 withthe exception of one amino acid substitution and one amino acidinsertion, one amino acid substitution and one amino acid deletion, orone amino acid insertion and one amino acid deletion. A polypeptide ofthe invention may comprise the amino acid sequence of SEQ ID NOs: 1-3,with the exception of one amino acid substitution, one amino acidinsertion and one amino acid deletion.

Inserted amino acids and replacement amino acids may be naturallyoccurring amino acids or may be non-naturally occurring amino acids and,for example, may contain a non-natural side chain, and/or be linkedtogether via non-native peptide bonds. Such altered peptide ligands arediscussed further in Douat-Casassus et al., J. Med. Chem, 2007 Apr. 5;50(7):1598-609 and Hoppes et al., J. Immunol 2014 Nov. 15;193(10):4803-13 and references therein). If more than one amino acidresidue is substituted and/or inserted, the replacement/inserted aminoacid residues may be the same as each other or different from oneanother. Each replacement amino acid may have a different side chain tothe amino acid being replaced.

Amino acid substitutions may be conservative, by which it is meant thesubstituted amino acid has similar chemical properties to the originalamino acid. A skilled person would understand which amino acids sharesimilar chemical properties. For example, the following groups of aminoacids share similar chemical properties such as size, charge andpolarity: Group 1 Ala, Ser, Thr, Pro, Gly; Group 2 asp, asn, glu, gin;Group 3 His, Arg, Lys; Group 4 Met, Leu, lie, Val, Cys; Group 5 Phe ThyTrp.

Preferably, polypeptides of the invention bind to MHC in the peptidebinding groove of the MHC molecule. Generally the amino acidmodifications described above will not impair the ability of the peptideto bind MHC. In a preferred embodiment, the amino acid modificationsimprove the ability of the peptide to bind MHC. For example, mutationsmay be made at positions which anchor the peptide to MHC. Such anchorpositions and the preferred residues at these locations are known in theart, particularly for peptides which bind HLA-A*02 (see, e. g. Parkhurstet al., J. Immunol. 1996 Sep. 15; 157(6):2539-48 and Parker et al. JImmunol. 1992 Dec. 1; 149(11):3580-7). Amino acids residues at position2, and at the C terminal end, of the peptide are considered primaryanchor positions. Preferred anchor residues may be different for eachHLA type. The preferred amino acids in position 2 for HLA-A*02 are Leu,lie, Val or Met. At the C terminal end, a valine or leucine is favoured.

A peptide of the invention may be used to elicit an immune response. Ifthis is the case, it is important that the immune response is specificto the intended target in order to avoid the risk of unwanted sideeffects that may be associated with an “off target” immune response.Therefore, it is preferred that the amino acid sequence of a peptide ofthe invention does not match the amino acid sequence of a peptide fromany other protein(s), in particular, that of another human protein. Aperson of skill in the art would understand how to search a database ofknown protein sequences to ascertain whether a peptide according to theinvention is present in another protein.

Peptides of the invention may be conjugated to additional moieties suchas carrier molecules or adjuvants for use as vaccines (for specificexamples see Liu et al. Bioconjug Chem. 2015 May 20; 26(5): 791-801 andreferences therein). The peptides may be biotinylated or include a tag,such as a His tag. Examples of adjuvants used in cancer vaccines includemicrobes, such as the bacterium Bacillus Calmette-Guerin (BCG), and/orsubstances produced by bacteria, such as Detox B (an oil dropletemulsion of monophosphoryl lipid A and mycobacterial cell wallskeleton). KLH (keyhole limpet hemocyanin) and bovine serum albumin areexamples of suitable carrier proteins used in vaccine compositionsAlternatively or additionally, the peptide may attached, covalently orotherwise, to proteins such as MHC molecules and/or antibodies (forexample, see King et al. Cancer Immunol Immunother. 2013 June;62(6):1093-105). Alternatively or additionally the peptides may beencapsulated into liposomes (for example see Adamina et al Br J Cancer.2004 Jan. 12; 90(1):263-9). Such modified peptides may not correspond toany molecule that exists in nature.

Peptides of the invention can be synthesised easily by Merrifieldsynthesis, also known as solid phase synthesis, or any other peptidesynthesis methodology. GMP grade peptide is produced by solid-phasesynthesis techniques by Multiple Peptide Systems, San Diego, Calif. Assuch, the peptides may be immobilised, for example to a solid supportsuch as a bead. Alternatively, the peptide may be recombinantlyproduced, if so desired, in accordance with methods known in the art.Such methods typically involve the use of a vector comprising a nucleicacid sequence encoding the peptide to be expressed, to express thepolypeptide in vivo; for example, in bacteria, yeast, insect ormammalian cells. Alternatively, in vitro cell-free systems may be used.Such systems are known in the art and are commercially available forexample from Life Technologies, Paisley, UK. The peptides may beisolated and/or may be provided in substantially pure form. For example,they may be provided in a form which is substantially free of otherpeptides or proteins.

In a second aspect the invention provides a complex of the peptide ofthe first aspect and an MHC molecule. Preferably, the peptide is boundto the peptide binding groove of the MHC molecule. The MHC molecule maybe MHC class I. The MHC class I molecule may be selected from HLA-A*02,HLA-A*01, HLA-A*03, HLA-A11, HLA-A23, HLA-A24, HLA-B*07, HLA-B*08,HLA-B40, HLA-B44, HLA-B15, HLA-C*04, HLA*C*03 HLA-C*07. As is known tothose skilled in the art there are allelic variants of the above HLAtypes, all of which are encompassed by the present invention. A fulllist of HLA alleles can be found on the EMBL Immune PolymorphismDatabase (http://www.ebi.ac.uk/ipd/imgt/hla/allele.html; Robinson et al.Nucleic Acids Research (2015) 43:D423-431). The MHC molecule may beHLA-A*02.

The complex of the invention may be isolated and/or in a substantiallypure form. For example, the complex may be provided in a form which issubstantially free of other peptides or proteins. It should be notedthat in the context of the present invention, the term “MHC molecule”includes recombinant MHC molecules, non-naturally occurring MHCmolecules and functionally equivalent fragments of MHC, includingderivatives or variants thereof, provided that peptide binding isretained. For example, MHC molecules may be fused to a therapeuticmoiety, attached to a solid support, in soluble form, attached to a tag,biotinylated and/or in multimeric form. The peptide may be covalentlyattached to the MHC.

Methods to produce soluble recombinant MHC molecules with which peptidesof the invention can form a complex are known in the art. Suitablemethods include, but are not limited to, expression and purificationfrom E. coli cells or insect cells. A suitable method is provided inExample 2 herein. Alternatively, MHC molecules may be producedsynthetically, or using cell free systems.

Polypeptides and/or polypeptide-MHC complexes of the invention may beassociated (covalently or otherwise) with a moiety capable of elicitinga therapeutic effect. Such a moiety may be a carrier protein which isknown to be immunogenic. KLH (keyhole limpet hemocyanin) and bovineserum albumin are examples of suitable carrier proteins used in vaccinecompositions. Alternatively, the peptides and/or peptide-MHC complexesof the invention may be associated with a fusion partner. Fusionpartners may be used for detection purposes, or for attaching saidpeptide or MHC to a solid support, or for MHC oligomerisation. The MHCcomplexes may incorporate a biotinylation site to which biotin can beadded, for example, using the BirA enzyme (O'Callaghan et al., 1999 Jan.1; 266(1):9-15). Other suitable fusion partners include, but are notlimited to, fluorescent, or luminescent labels, radiolabels, nucleicacid probes and contrast reagents, antibodies, or enzymes that produce adetectable product. Detection methods may include flow cytometry,microscopy, electrophoresis or scintillation counting. Fusion partnersmay include cytokines, such as interleukin 2, interferon alpha, andgranulocyte-macrophage colony-stimulating factor.

Peptide-MHC complexes of the invention may be provided in soluble form,or may be immobilised by attachment to a suitable solid support.Examples of solid supports include, but are not limited to, a bead, amembrane, sepharose, a magnetic bead, a plate, a tube, a column.Peptide-MHC complexes may be attached to an ELISA plate, a magneticbead, or a surface plasmon resonance biosensor chip. Methods ofattaching peptide-MHC complexes to a solid support are known to theskilled person, and include, for example, using an affinity bindingpair, e.g. biotin and streptavidin, or antibodies and antigens. In apreferred embodiment peptide-MHC complexes are labelled with biotin andattached to streptavidin-coated surfaces.

Peptide-MHC complexes of the invention may be in multimeric form, forexample, dimeric, or tetrameric, or pentameric, or octomeric, orgreater. Examples of suitable methods for the production of multimericpeptide MHC complexes are described in Greten et al., Clin. Diagn. Lab.Immunol. 2002 March; 9(2):216-20 and references therein. In general,peptide-MHC multimers may be produced using peptide-MHC tagged with abiotin residue and complexed through fluorescent labelled streptavidin.Alternatively, multimeric peptide-MHC complexes may be formed by usingimmunoglobulin as a molecular scaffold. In this system, theextracellular domains of MHC molecules are fused with the constantregion of an immunoglobulin heavy chain separated by a short amino acidlinker. Peptide-MHC multimers have also been produced using carriermolecules such as dextran (WO02072631). Multimeric peptide MHC complexescan be useful for improving the detection of binding moieties, such as Tcell receptors, which bind said complex, because of avidity effects.

The polypeptides of the invention may be presented on the surface of acell in complex with MHC. Thus, the invention also provides a cellpresenting on its surface a complex of the invention. Such a cell may bea mammalian cell, preferably a cell of the immune system, and inparticular a specialised antigen presenting cell such as a dendriticcell or a B cell. Other preferred cells include T2 cells (Hosken, etal., Science. 1990 Apr. 20; 248(4953):367-70). Cells presenting thepolypeptide or complex of the invention may be isolated, preferably inthe form of a population, or provided in a substantially pure form. Saidcells may not naturally present the complex of the invention, oralternatively said cells may present the complex at a level higher thanthey would in nature. Such cells may be obtained by pulsing said cellswith the polypeptide of the invention. Pulsing involves incubating thecells with the polypeptide for several hours using polypeptideconcentrations typically ranging from 10⁻⁵ to 10⁻¹² M. Said cells mayadditionally be transduced with HLA molecules, such as HLA-A*02 tofurther induce presentation of the peptide. Cells may be producedrecombinantly. Cells presenting peptides of the invention may be used toisolate T cells and T cell receptors (TCRs) which are activated by, orbind to, said cells, as described in more detail below.

In a third aspect, the invention provides a nucleic acid moleculecomprising a nucleic acid sequence encoding the polypeptide of the firstaspect of the invention. The nucleic acid may be cDNA. The nucleic acidmolecule may consist essentially of a nucleic acid sequence encoding thepeptide of the first aspect of the invention or may encode only thepeptide of the invention, i.e. encode no other peptide or polypeptide.

Such a nucleic acid molecule can be synthesised in accordance withmethods known in the art. Due to the degeneracy of the genetic code, oneof ordinary skill in the art will appreciate that nucleic acid moleculesof different nucleotide sequence can encode the same amino acidsequence.

In a fourth aspect, the invention provides a vector comprising a nucleicacid sequence according to the third aspect of the invention. The vectormay include, in addition to a nucleic acid sequence encoding only apeptide of the invention, one or more additional nucleic acid sequencesencoding one or more additional peptides. Such additional peptides may,once expressed, be fused to the N-terminus or the C-terminus of thepeptide of the invention. In one embodiment, the vector includes anucleic acid sequence encoding a peptide or protein tag such as, forexample, a biotinylation site, a FLAG-tag, a MYC-tag, an HA-tag, aGST-tag, a Strep-tag or a poly-histidine tag.

Suitable vectors are known in the art as is vector construction,including the selection of promoters and other regulatory elements, suchas enhancer elements. The vector utilised in the context of the presentinvention desirably comprises sequences appropriate for introductioninto cells. For instance, the vector may be an expression vector, avector in which the coding sequence of the polypeptide is under thecontrol of its own cis-acting regulatory elements, a vector designed tofacilitate gene integration or gene replacement in host cells, and thelike.

In the context of the present invention, the term “vector” encompasses aDNA molecule, such as a plasmid, bacteriophage, phagemid, virus or othervehicle, which contains one or more heterologous or recombinantnucleotide sequences (e.g., an above-described nucleic acid molecule ofthe invention, under the control of a functional promoter and, possibly,also an enhancer) and is capable of functioning as a vector in the senseunderstood by those of ordinary skill in the art. Appropriate phage andviral vectors include, but are not limited to, lambda (λ) bacteriophage,EMBL bacteriophage, simian virus 40, bovine papilloma virus,Epstein-Barr virus, adenovirus, herpes virus, vaccinia virus, Moloneymurine leukemia virus, Harvey murine sarcoma virus, murine mammary tumorvirus, lentivirus and Rous sarcoma virus.

In a fifth aspect, the invention provides a cell comprising the vectorof the fourth aspect of the invention. The cell may be an antigenpresenting cell and is preferably a cell of the immune system. Inparticular, the cell may be a specialised antigen presenting cell suchas a dendritic cell or a B cell. The cell may be a mammalian cell.

Peptides and complexes of the invention can be used to identify and/orisolate binding moieties that bind specifically to the peptide and/orthe complex of the invention. Such binding moieties may be used asimmunotherapeutic reagents and may include antibodies and TCRs.

In a sixth aspect, the invention provides a binding moiety that bindsthe polypeptide of the invention. Preferably the binding moiety bindsthe peptide when said peptide is in complex with MHC. In the latterinstance, the binding moiety may bind partially to the MHC, providedthat it also binds to the peptide. The binding moiety may bind only thepeptide, and that binding may be specific. The binding moiety may bindonly the peptide MHC complex and that binding may be specific.

When used with reference to binding moieties that bind the complex ofthe invention, “specific” is generally used herein to refer to thesituation in which the binding moiety does not show any significantbinding to one or more alternative polypeptide-MHC complexes other thanthe polypeptide-MHC complex of the invention. TCRs that bind to one ormore, and in particular several, antigens presented by cells that arenot the intended target of the TCR, pose an increased risk of toxicitywhen administered in vivo because of potential off target reactivity.Such highly cross-reactive TCRs are not suitable for therapeutic use.

The binding moiety may be a T cell receptor (TCR). TCRs are describedusing the International Immunogenetics (IMGT) TCR nomenclature, andlinks to the IMGT public database of TCR sequences. The unique sequencesdefined by the IMGT nomenclature are widely known and accessible tothose working in the TCR field. For example, they can be found in the “Tcell Receptor Factsbook”, (2001) LeFranc and LeFranc, Academic Press,ISBN 0-12-441352-8; Lefranc, (2011), Cold Spring Harb Protoc 2011(6):595-603; Lefranc, (2001), Curr Protoc Immunol Appendix 1: Appendix 10;Lefranc, (2003), Leukemia 17(1): 260-266, and on the IMGT website(IMGT.org)

The TCRs of the invention may be in any format known to those in theart. For example, the TCRs may be as heterodimers, or aa or pphomodimers.

Alpha-beta heterodimeric TCRs have an alpha chain and a beta chain.Broadly, each chain comprises variable, joining and constant region, andthe beta chain also usually contains a short diversity region betweenthe variable and joining regions, but this diversity region is oftenconsidered as part of the joining region. Each variable region comprisesthree hypervariable CDRs (Complementarity Determining Regions) embeddedin a framework sequence; CDR3 is believed to be the main mediator ofantigen recognition. There are several types of alpha chain variable(Vα) regions and several types of beta chain variable (Vβ) regionsdistinguished by their framework, CDR1 and CDR2 sequences, and by apartly defined CDR3 sequence.

The TCRs of the invention may not correspond to TCRs as they exist innature. For example, they may comprise alpha and beta chain combinationsthat are not present in a natural repertoire. Alternatively oradditionally they may be soluble, and/or the alpha and/or beta chainconstant domain may be truncated relative to the native/naturallyoccurring TRAC/TRBC sequences such that, for example, the C terminaltransmembrane domain and intracellular regions are not present. Suchtruncation may result in removal of the cysteine residues from TRAC/TRBCthat form the native interchain disulphide bond.

In addition the TRAC/TRBC domains may contain modifications. Forexample, the alpha chain extracellular sequence may include amodification relative to the native/naturally occurring TRAC wherebyamino acid T48 of TRAC, with reference to IMGT numbering, is replacedwith C48. Likewise, the beta chain extracellular sequence may include amodification relative to the native/naturally occurring TRBC1 or TRBC2whereby S57 of TRBC1 or TRBC2, with reference to IMGT numbering, isreplaced with C57. These cysteine substitutions relative to the nativealpha and beta chain extracellular sequences enable the formation of anon-native interchain disulphide bond which stabilises the refoldedsoluble TCR, i.e. the TCR formed by refolding extracellular alpha andbeta chains (WO 03/020763). This non-native disulphide bond facilitatesthe display of correctly folded TCRs on phage. (Li et al., NatBiotechnol 2005 March; 23(3):349-54). In addition the use of the stabledisulphide linked soluble TCR enables more convenient assessment ofbinding affinity and binding half-life. Alternative positions for theformation of a non-native disulphide bond are described in WO 03/020763.These include Thr 45 of exon 1 of TRAC*01 and Ser 77 of exon 1 ofTRBC1*01 or TRBC2*01; Tyr 10 of exon 1 of TRAC*01 and Ser 17 of exon 1of TRBC1*01 or TRBC2*01; Thr 45 of exon 1 of TRAC*01 and Asp 59 of exon1 of TRBC1*01 or TRBC2*01; and Ser 15 of exon 1 of TRAC*01 and Glu 15 ofexon 1 of TRBC1*01 or TRBC2*01. TCRs with a non-native disulphide bondmay be full length or may be truncated.

TCRs of the invention may be in single chain format (such as thosedescribed in WO9918129). Single chain TCRs include as TCR polypeptidesof the type: Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ or Vα-Cα-L-Vβ-Cβ,optionally in the reverse orientation, wherein Vα and Vβ are TCR α and βvariable regions respectively, Cα and Cβ are TCR α and β constantregions respectively, and L is a linker sequence. Single chain TCRs maycontain a non-native disulphide bond. The TCR may be in a soluble form(i.e. having no transmembrane or cytoplasmic domains), or may containfull length alpha and beta chains. The TCR may be provided on thesurface of a cell, such as a T cell.

TCRs of the invention may be engineered to include mutations. Methodsfor producing mutated high affinity TCR variants such as phage displayand site directed mutagenesis and are known to those in the art (forexample see WO 04/044004 and Li et al., Nat Biotechnol 2005 March;23(3):349-54).). Preferably, mutations to improve affinity are madewithin the variable regions of alpha and/or beta chains. More preferablymutations to improve affinity are made within the CDRs. There may bebetween 1 and 15 mutations in the alpha and or beta chain variableregions.

TCRs of the invention may also be may be labelled with an imagingcompound, for example a label that is suitable for diagnostic purposes.Such labelled high affinity TCRs are useful in a method for detecting aTCR ligand selected from CD1-antigen complexes, bacterial superantigens,and MHC-peptide/superantigen complexes, which method comprisescontacting the TCR ligand with a high affinity TCR (or a multimeric highaffinity TCR complex) which is specific for the TCR ligand; anddetecting binding to the TCR ligand. In multimeric high affinity TCRcomplexes such as those described in Zhu et al., J. Immunol. 2006 Mar.1; 176(5):3223-32, (formed, for example, using biotinylatedheterodimers) fluorescent streptavidin (commercially available) can beused to provide a detectable label. A fluorescently-labelled multimer issuitable for use in FACS analysis, for example to detect antigenpresenting cells carrying the peptide for which the high affinity TCR isspecific.

A TCR of the present invention (or multivalent complex thereof) mayalternatively or additionally be associated with (e.g. covalently orotherwise linked to) a therapeutic agent which may be, for example, atoxic moiety for use in cell killing, or an immunostimulating agent suchas an interleukin or a cytokine. A multivalent high affinity TCR complexof the present invention may have enhanced binding capability for a TCRligand compared to a non-multimeric wild-type or high affinity T cellreceptor heterodimer. Thus, the multivalent high affinity TCR complexesaccording to the invention are particularly useful for tracking ortargeting cells presenting particular antigens in vitro or in vivo, andare also useful as intermediates for the production of furthermultivalent high affinity TCR complexes having such uses. The highaffinity TCR or multivalent high affinity TCR complex may therefore beprovided in a pharmaceutically acceptable formulation for use in vivo.

High affinity TCRs of the invention may be used in the production ofsoluble bi-specific reagents. A preferred embodiment is a reagent whichcomprises a soluble TCR, fused via a linker to an anti-CD3 specificantibody fragment. Further details including how to produce suchreagents are described in WO10/133828.

In a further aspect, the invention provides nucleic acid encoding theTCR of the invention, a TCR expression vector comprising nucleic acidencoding a TCR of the invention, as well as a cell harbouring such avector. The TCR may be encoded either in a single open reading frame ortwo distinct open reading frames. Also included in the scope of theinvention is a cell harbouring a first expression vector which comprisesnucleic acid encoding an alpha chain of a TCR of the invention, and asecond expression vector which comprises nucleic acid encoding a betachain of a TCR of the invention. Alternatively, one vector may encodeboth an alpha and a beta chain of a TCR of the invention.

A further aspect of the invention provides a cell displaying on itssurface a TCR of the invention. The cell may be a T cell, or otherimmune cell. The T cell may be modified such that it does not correspondto a T cell as it exists in nature. For example, the cell may betransfected with a vector encoding a TCR of the invention such that theT cell expresses a further TCR in addition to the native TCR.Additionally or alternatively the T cell may be modified such that it isnot able to present the native TCR. There are a number of methodssuitable for the transfection of T cells with DNA or RNA encoding theTCRs of the invention (see for example Robbins et al., J. Immunol. 2008May 1; 180(9):6116-31). T cells expressing the TCRs of the invention aresuitable for use in adoptive therapy-based treatment of diseases such ascancers. As will be known to those skilled in the art there are a numberof suitable methods by which adoptive therapy can be carried out (seefor example Rosenberg et al., Nat Rev Cancer. 2008 April; 8(4):299-308).

The TCRs of the invention intended for use in adoptive therapy aregenerally glycosylated when expressed by the transfected T cells. As iswell known, the glycosylation pattern of transfected TCRs may bemodified by mutations of the transfected gene (Kuball J et al., J ExpMed. 2009 Feb. 16; 206(2):463-75).

Examples of TCR variable region amino acid sequences that are able tospecifically recognise peptides of the invention are provided in theFigures. TCRs having 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identityto the sequences provided are also contemplated by the invention. TCRswith the same alpha and beta chain usage are also included in theinvention.

The binding moiety of the invention may be an antibody. The term“antibody” as used herein refers to immunoglobulin molecules andimmunologically active portions of immunoglobulin molecules, i.e.,molecules that contain an antigen binding site that specifically bindsan antigen, whether natural or partly or wholly synthetically produced.The term “antibody” includes antibody fragments, derivatives, functionalequivalents and homologues of antibodies, humanised antibodies,including any polypeptide comprising an immunoglobulin binding domain,whether natural or wholly or partially synthetic and any polypeptide orprotein having a binding domain which is, or is homologous to, anantibody binding domain. Chimeric molecules comprising an immunoglobulinbinding domain, or equivalent, fused to another polypeptide aretherefore included. Cloning and expression of chimeric antibodies aredescribed in EP-A-0120694 and EP-A-0125023. A humanised antibody may bea modified antibody having the variable regions of a non-human, e.g.murine, antibody and the constant region of a human antibody. Methodsfor making humanised antibodies are described in, for example, U.S. Pat.No. 5,225,539. Examples of antibodies are the immunoglobulin isotypes(e.g., IgG, IgE, IgM, IgD and IgA) and their isotypic subclasses;fragments which comprise an antigen binding domain such as Fab, scFv,Fv, dAb, Fd; and diabodies. Antibodies may be polyclonal or monoclonal.A monoclonal antibody may be referred to herein as “mab”.

It is possible to take an antibody, for example a monoclonal antibody,and use recombinant DNA technology to produce other antibodies orchimeric molecules which retain the specificity of the originalantibody. Such techniques may involve introducing DNA encoding theimmunoglobulin variable region, or the complementary determining regions(CDRs), of an antibody to the constant regions, or constant regions plusframework regions, of a different immunoglobulin (see, for instance,EP-A-184187, GB 2188638A or EP-A-239400). A hybridoma (or other cellthat produces antibodies) may be subject to genetic mutation or otherchanges, which may or may not alter the binding specificity ofantibodies produced.

It has been shown that fragments of a whole antibody can perform thefunction of binding antigens. Examples of binding fragments are (i) theFab fragment consisting of VL, VH, CL and CH1 domains; (ii) the Fdfragment consisting of the VH and CH1 domains; (iii) the Fv fragmentconsisting of the VL and VH domains of a single antibody; (iv) the dAbfragment (Ward, E. S. et al., Nature. 1989 Oct. 12; 341(6242):544-6)which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab′)2fragments, a bivalent fragment comprising two linked Fab fragments (vii)single chain Fv molecules (scFv), wherein a VH domain and a VL domainare linked by a peptide linker which allows the two domains to associateto form an antigen binding site (Bird et al., Science. 1988 Oct. 21;242(4877):423-6; Huston et al., Proc Natl Acad Sci USA. 1988 August;85(16):5879-83); (viii) bispecific single chain Fv dimers(PCT/US92/09965) and (ix) “diabodies”, multivalent or multispecificfragments constructed by gene fusion (WO94/13804; P. Hollinger et al.,Proc Natl Acad Sci USA. 1993 Jul. 15; 90(14):6444-8). Diabodies aremultimers of polypeptides, each polypeptide comprising a first domaincomprising a binding region of an immunoglobulin light chain and asecond domain comprising a binding region of an immunoglobulin heavychain, the two domains being linked (e.g. by a peptide linker) butunable to associate with each other to form an antigen binding site:antigen binding sites are formed by the association of the first domainof one polypeptide within the multimer with the second domain of anotherpolypeptide within the multimer (WO94/13804). Where bispecificantibodies are to be used, these may be conventional bispecificantibodies, which can be manufactured in a variety of ways (Hollinger &Winter, Curr Opin Biotechnol. 1993 August; 4(4):446-9), e.g. preparedchemically or from hybrid hybridomas, or may be any of the bispecificantibody fragments mentioned above. It may be preferable to use scFvdimers or diabodies rather than whole antibodies. Diabodies and scFv canbe constructed without an Fc region, using only variable domains,potentially reducing the effects of anti-idiotypic reaction. Other formsof bispecific antibodies include the single chain “Janusins” describedin Traunecker et al., EMBO J. 1991 December; 10(12):3655-9). Bispecificdiabodies, as opposed to bispecific whole antibodies, may also be usefulbecause they can be readily constructed and expressed in E. coli.Diabodies (and many other polypeptides such as antibody fragments) ofappropriate binding specificities can be readily selected using phagedisplay (WO94/13804) from libraries. If one arm of the diabody is to bekept constant, for instance, with a specificity directed against antigenX, then a library can be made where the other arm is varied and anantibody of appropriate specificity selected. An “antigen bindingdomain” is the part of an antibody which comprises the area whichspecifically binds to and is complementary to part or all of an antigen.Where an antigen is large, an antibody may only bind to a particularpart of the antigen, which part is termed an epitope. An antigen bindingdomain may be provided by one or more antibody variable domains. Anantigen binding domain may comprise an antibody light chain variableregion (VL) and an antibody heavy chain variable region (VH).

The binding moiety may be an antibody-like molecule that has beendesigned to specifically bind a peptide-MHC complex of the invention. Ofparticular preference are TCR-mimic antibodies, such as, for examplethose described in WO2007143104 and Sergeeva et al., Blood. 2011 Apr.21; 117(16):4262-72 and/or Dahan and Reiter. Expert Rev Mol Med. 2012Feb. 24; 14:e6.

Also encompassed within the present invention are binding moieties basedon engineered protein scaffolds. Protein scaffolds are derived fromstable, soluble, natural protein structures which have been modified toprovide a binding site for a target molecule of interest. Examples ofengineered protein scaffolds include, but are not limited to,affibodies, which are based on the Z-domain of staphylococcal protein Athat provides a binding interface on two of its a-helices (Nygren, FEBSJ. 2008 June; 275(11):2668-76); anticalins, derived from lipocalins,that incorporate binding sites for small ligands at the open end of abeta-barrel fold (Skerra, FEBS J. 2008 June; 275(11):2677-83),nanobodies, and DARPins. Engineered protein scaffolds are typicallytargeted to bind the same antigenic proteins as antibodies, and arepotential therapeutic agents. They may act as inhibitors or antagonists,or as delivery vehicles to target molecules, such as toxins, to aspecific tissue in vivo (Gebauer and Skerra, Curr Opin Chem Biol. 2009June; 13(3):245-55). Short peptides may also be used to bind a targetprotein. Phylomers are natural structured peptides derived frombacterial genomes. Such peptides represent a diverse array of proteinstructural folds and can be used to inhibit/disrupt protein-proteininteractions in vivo (Watt, Nat Biotechnol. 2006 February;24(2):177-83)].

In another aspect, the invention further provides a peptide of theinvention, a nucleic acid molecule of the invention, a vector of theinvention, a cell of the invention or a binding moiety of the inventionfor use in medicine. The peptide, complex, nucleic acid, vector, cell orbinding moiety may be used for in the treatment or prevention of cancer,in particular, breast, colon and oesophageal cancers

In a further aspect, the invention provides a pharmaceutical compositioncomprising a peptide of the invention, a nucleic acid molecule of theinvention, a vector of the invention, a cell of the invention or abinding moiety of the invention together with a pharmaceuticallyacceptable carrier.

This pharmaceutical composition may be in any suitable form, (dependingupon the desired method of administering it to a patient). It may beprovided in unit dosage form, will generally be provided in a sealedcontainer and may be provided as part of a kit. Such a kit wouldnormally (although not necessarily) include instructions for use. It mayinclude a plurality of said unit dosage forms. Suitable compositions andmethods of administration are known to those skilled in the art, forexample see, Johnson et al., Blood. 2009 Jul. 16; 114(3):535-46, withreference to clinical trial numbers NCI-07-C-0175 and NCI-07-C-0174.Cells in accordance with the invention will usually be supplied as partof a sterile, pharmaceutical composition which will normally include apharmaceutically acceptable carrier. For example, T cells transfectedwith TCRs of the invention may be provided in pharmaceutical compositiontogether with a pharmaceutically acceptable carrier. Thepharmaceutically acceptable carrier may be a cream, emulsion, gel,liposome, nanoparticle or ointment.

The pharmaceutical composition may be adapted for administration by anyappropriate route such as a parenteral (including subcutaneous,intramuscular, or intravenous), enteral (including oral or rectal),inhalation or intranasal routes. Such compositions may be prepared byany method known in the art of pharmacy, for example by mixing theactive ingredient with the carrier(s) or excipient(s) under sterileconditions.

Dosages of the substances of the present invention can vary between widelimits, depending upon the disease or disorder to be treated (such ascancer, viral infection or autoimmune disease), the age and condition ofthe individual to be treated, etc. For example, a suitable dose rangefor a reagent comprising a soluble TCR fused to an anti-CD3 domain maybe between 25 ng/kg and 50 μg/kg. A physician will ultimately determineappropriate dosages to be used.

The polypeptide of the invention may be provided in the form of avaccine composition. The vaccine composition may be useful for thetreatment or prevention of cancer. All such compositions are encompassedin the present invention. As will be appreciated, vaccines may takeseveral forms (Schlom, J Natl Cancer Inst. 2012 Apr. 18;104(8):599-613). For example, the peptide of the invention may be useddirectly to immunise patients (Salgaller, Cancer Res. 1996 Oct. 15;56(20):4749-57 and Marchand, Int J Cancer. 1999 Jan. 18; 80(2):219-30).The vaccine composition may include additional peptides such that thepeptide of the invention is one of a mixture of peptides. Adjuvants maybe added to the vaccine composition to augment the immune response

Alternatively the vaccine composition may take the form of an antigenpresenting cell displaying the peptide of the invention in complex withMHC. Preferably the antigen presenting cell is an immune cell, morepreferably a dendritic cell. The peptide may be pulsed onto the surfaceof the cell (Thurner, J Exp Med. 1999 Dec. 6; 190(11):1669-78), ornucleic acid encoding for the peptide of the invention may be introducedinto dendritic cells (for example by electroporation. Van Tendeloo,Blood. 2001 Jul. 1; 98(1):49-56).

The polypeptides, complexes, nucleic acid molecules, vectors, cells andbinding moieties of the invention may be non-naturally occurring and/orpurified and/or engineered and/or recombinant and/or isolated and/orsynthetic.

The invention also provides a method of identifying a binding moietythat binds a complex of the invention, the method comprising contactinga candidate binding moiety with the complex and determining whether thecandidate binding moiety binds the complex. Methods to determine bindingto polypeptide-MHC complexes are well known in the art. Preferredmethods include, but are not limited to, surface plasmon resonance, orany other biosensor technique, ELISA, flow cytometry, chromatography,microscopy. Alternatively, or in addition, binding may be determined byfunctional assays in which a biological response is detected uponbinding, for example, cytokine release or cell apoptosis.

The candidate binding moiety may be a binding moiety of the type alreadydescribed, such as a TCR or an antibody. Said binding moiety may beobtained using methods that are known in the art.

For example, antigen binding T cells and TCRs have traditionally beenisolated from fresh blood obtained from patients or healthy donors. Sucha method involves stimulating T cells using autologous DCs, followed byautologous B cells, pulsed with the polypeptide of the invention.Several rounds of stimulation may be carried out, for example three orfour rounds. Activated T cells may then be tested for specificity bymeasuring cytokine release in the presence of T2 cells pulsed with thepeptide of the invention (for example using an IFNγ ELISpot assay).Activated cells may then be sorted by fluorescence-activated cellsorting (FACS) using labelled antibodies to detect intracellularcytokine production (e.g. IFNγ), or expression of a cell surface marker(such as CD137). Sorted cells may be expanded and further validated, forexample, by ELISpot assay and/or cytotoxicity against target cellsand/or staining by peptide-MHC tetramer. The TCR chains from validatedclones may then be amplified by rapid amplification of cDNA ends (RACE)and sequenced.

Alternatively, TCRs and antibodies may be obtained from displaylibraries in which the peptide MHC complex of the invention is used topan the library The production of antibody libraries using phage displayis well known in the art, for example see Aitken, Antibody phagedisplay: Methods and Protocols (2009, Humana, New York). TCRs can bedisplayed on the surface of phage particles and yeast particles forexample, and such libraries have been used for the isolation of highaffinity variants of TCR derived from T cell clones (as described inWO04044004 and Li et al. Nat Biotechnol. 2005 March; 23(3):349-54 andWO9936569). It has been demonstrated more recently that TCR phagelibraries can be used to isolate TCRs with novel antigen specificity.Such libraries are typically constructed with alpha and beta chainsequences corresponding to those found in a natural repertoire. However,the random combination of these alpha and beta chain sequences, whichoccurs during library creation, produces a repertoire of TCRs notpresent in nature (as described in WO2015/136072, PCT/EP2016/071757,PCT/EP2016/071761, PCT/EP2016/071762, PCT/EP2016/071765,PCT/EP2016/071767, PCT/EP2016/071768, PCT/EP2016/071771 andPCT/EP2016/071772) In a preferred embodiment, the peptide-MHC complex ofthe invention may be used to screen a library of diverse TCRs displayedon the surface of phage particles. The TCRs displayed by said librarymay not correspond to those contained in a natural repertoire, forexample, they may contain alpha and beta chain pairing that would not bepresent in vivo, and or the TCRs may contain non-natural mutations andor the TCRs may be in soluble form. Screening may involve panning thephage library with peptide-MHC complexes of the invention andsubsequently isolating bound phage. For this purpose peptide-MHCcomplexes may be attached to a solid support, such as a magnet bead, orcolumn matrix and phage bound peptide MHC complexes isolated, with amagnet, or by chromatography, respectively. The panning steps may berepeated several times for example three or four times. Isolated phagemay be further expanded in E. coli cells. Isolated phage particles maybe tested for specific binding peptide-MHC complexes of the invention.Binding can be detected using techniques including, but not limited to,ELISA, or SPR for example using a BiaCore instrument. The DNA sequenceof the T cell receptor displayed by peptide-MHC binding phage can befurther identified by standard PCR methods.

Preferred or optional features of each aspect of the invention are asfor each of the other aspects mutatis mutandis. The prior art documentsmentioned herein are incorporated by reference to the fullest extentpermitted by law.

The present invention will be further illustrated in the followingExamples and Figures which are given for illustration purposes only andare not intended to limit the invention in any way.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1 to 3 show the respective fragmentation spectra for the peptidesof SEQ ID NOS: 1 to 3, eluted from cells. A table highlighting thematching ions is shown below each spectrum.

FIG. 4 shows ELISA plates demonstrating the specificity of TCRs for acomplex of the peptide of SEQ ID NO: 1 and HLA-A*02, by comparingbinding with other peptide-HLA-A*02 complexes.

FIG. 5 shows the amino acid sequences of the respective alpha chain andbeta chain variable chains of the TCRs of FIG. 4.

EXAMPLES Example 1—Identification of Target-Derived Peptides by MassSpectrometry

Presentation of HLA-restricted peptides derived from LGSN on the surfaceof tumour cell lines was investigated using mass spectrometry.

Method

Immortalised cell lines obtained from commercial sources were maintainedand expanded under standard conditions.

Class I HLA complexes were purified by immunoaffinity using commerciallyavailable anti-HLA antibodies BB7.1 (anti-HLA-B*07), BB7.2(anti-HLA-A*02) and W6/32 (anti-Class 1). Briefly, cells were lysed inbuffer containing non-ionic detergent NP-40 (0.5% v/v) at 5×10⁷ cellsper ml and incubated at 4° C. for 1 h with agitation/mixing. Cell debriswas removed by centrifugation and supernatant pre-cleared usingproteinA-Sepharose. Supernatant was passed over 5 ml of resin containing8 mg of anti-HLA antibody immobilised on a proteinA-Sepharose scaffold.Columns were washed with low salt and high salt buffers and complexeseluted in acid. Eluted peptides were separated from HLA complexes byreversed phase chromatography using a solid phase extraction cartridge(Phenomenex). Bound material was eluted from the column and reduced involume using a vacuum centrifuge.

Peptides were separated by high pressure liquid chromatography (HPLC) ona Dionex Ultimate 3000 system using a C18 column (Phenomenex). Peptideswere loaded in 98% buffer A (0.1% aqueous trifluoroacetic acid (TFA))and 2% buffer B (0.1% TFA in acetonitrile). Peptides were eluted using astepped gradient of B (2-60%) over 20 min. Fractions were collected atone minute intervals and lyophilised.

Peptides were analysed by nanoLCMS/MS using a Dionex Ultimate 3000nanoLC coupled to either AB Sciex Triple TOF 5600 or Thermo OrbitrapFusion mass spectrometers. Both machines were equipped withnanoelectrospray ion sources. Peptides were loaded onto an AcclaimPepMap 100 trap column (Dionex) and separated using an Acclaim PepMapRSLC column (Dionex). Peptides were loaded in mobile phase A (0.5%formic acid:water) and eluted using a gradient of buffer B(acetonitrile:0.5% formic acid) directly into the nanospray ionisationsource.

For peptide identification the mass spectrometer was operated using aninformation dependent acquisition (IDA) workflow. Information acquiredin these experiments was used to search the Uniprot database of humanproteins for peptides consistent with the fragmentation patterns seen,using Protein pilot software (Ab Sciex) and PEAKS software(Bioinformatics solutions). Peptides identified are assigned a score bythe software, based on the match between the observed and expectedfragmentation patterns.

Results

The polypeptides set out in table 1, corresponding to SEQ ID NOs: 1-3,were detected by mass spec following extraction from cancer cell lines.An example cell line from which the peptide was detected is indicated inthe table along with the HLA antibody used for immunoaffinitypurification.

Example SEQ ID Amino acid HLA cancer NO sequence antibody cell line 1ALGETFIRYFV HLA-A*02 NCI H2023 2 LSCLMAPSV class I BM1604 3 QILTPPQLclass I NCI H1944

FIGS. 1-3 show representative fragmentation patterns for the peptides ofSEQ ID NOS: 1-3 respectively. A table highlighting the matching ions isshown below each spectrum.

Example 2—Preparation of Recombinant Peptide-HLA Complexes

The following describes a suitable method for the preparation of solublerecombinant HLA loaded with TAA peptide.

Class I HLA molecules (HLA-heavy chain and HLA light-chain (β2m)) wereexpressed separately in E. coli as inclusion bodies, using appropriateconstructs. HLA-heavy chain additionally contained a C-terminalbiotinylation tag which replaces the transmembrane and cytoplasmicdomains (O'Callaghan et al. (1999) Anal. Biochem. 266: 9-15). E. colicells were lysed and inclusion bodies processed to approximately 80%purity.

Inclusion bodies of β2m and heavy chain were denatured separately indenaturation buffer (6 M guanidine, 50 mM Tris pH 8.1, 100 mM NaCl, 10mM DTT, 10 mM EDTA) for 30 mins at 37° C. Refolding buffer was preparedcontaining 0.4 M L-Arginine, 100 mM Tris pH 8.1, 2 mM EDTA, 3.1 mMcystamine dihydrochloride, 7.2 mM cystamine hydrochloride. Syntheticpeptide was dissolved in DMSO to a final concentration of 4 mg/ml andadded to the refold buffer at 4 mg/litre (final concentration). Then 30mg/litre β2m followed by 60 mg/litre heavy chain (final concentrations)are added. Refolding was allowed to reach completion at room temperaturefor at least 1 hour.

The refold mixture was then dialysed against 20 L of deionised water at4° C. for 16 h, followed by 10 mM Tris pH 8.1 for a further 16 h. Theprotein solution was then filtered through a 0.45 μm cellulose acetatefilter and loaded onto a POROS HQ anion exchange column (8 ml bedvolume) equilibrated with 20 mM Tris pH 8.1. Protein was eluted with alinear 0-500 mM NaCl gradient using an AKTA purifier (GE Healthcare).HLA-peptide complex eluted at approximately 250 mM NaCl, and peakfractions were collected, a cocktail of protease inhibitors (Calbiochem)was added and the fractions were chilled on ice.

Biotinylation tagged pHLA molecules were buffer exchanged into 10 mMTris pH 8.1, 5 mM NaCl using a GE Healthcare fast desalting columnequilibrated in the same buffer. Immediately upon elution, theprotein-containing fractions were chilled on ice and protease inhibitorcocktail (Calbiochem) was added. Biotinylation reagents were then added:1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCl2, and 5 μg/ml BirAenzyme (purified according to O'Callaghan et al., (1999) Anal. Biochem.266: 9-15). The mixture was then allowed to incubate at room temperatureovernight.

The biotinylated pHLA molecules were further purified by gel filtrationchromatography using an AKTA purifier with a GE Healthcare Superdex 75HR 10/30 column pre-equilibrated with filtered PBS. The biotinylatedpHLA mixture was concentrated to a final volume of 1 ml loaded onto thecolumn and was developed with PBS at 0.5 ml/min. Biotinylated pHLAmolecules eluted as a single peak at approximately 15 ml. Fractionscontaining protein were pooled, chilled on ice, and protease inhibitorcocktail was added. Protein concentration was determined using aCoomassie-binding assay (PerBio) and aliquots of biotinylated pHLAmolecules were stored frozen at −20° C.

Such peptide-MHC complexes may be used in soluble form or may beimmobilised through their C terminal biotin moiety on to a solidsupport, to be used for the detection of T cells and T cell receptorswhich bind said complex. For example, such complexes can be used inpanning phage libraries, performing ELISA assays and preparing sensorchips for BIACORE measurements.

Example 3—Identification of TCRs that Bind to a Peptide-MHC Complex ofthe Invention

Method

Antigen binding TCRs were obtained using peptides of the invention topan a TCR phage library. The library was constructed using alpha andbeta chain sequences obtained from a natural repertoire (as described inWO2015/136072, PCT/EP2016/071757, PCT/EP2016/071761, PCT/EP2016/071762,PCT/EP2016/071765, PCT/EP2016/071767, PCT/EP2016/071768,PCT/EP2016/071771 or PCT/EP2016/071772). The random combination of thesealpha and beta chain sequences, which occurs during library creation,produces a non-natural repertoire of alpha beta chain combinations.

TCRs obtained from the library were assessed by ELISA to confirmspecific antigen recognition. ELISA assays were performed as describedin WO2015/136072. Briefly, 96 well MaxiSorp ELISA plates were coatedwith streptavidin and incubated with the biotinylated peptide-HLAcomplex of the invention. TCR bearing phage clones were added to eachwell and detection carried out using an anti-M13-HRP antibody conjugate.Bound antibody was detected using the KPL labs TMB Microwell peroxidaseSubstrate System. The appearance of a blue colour in the well indicatedbinding of the TCR to the antigen. An absence of binding to alternativepeptide-HLA complexes indicated the TCR is not highly cross reactive.

Further confirmation that TCRs are able to bind a complex of comprisinga peptide HLA complex of the invention can be obtained by surfaceplasmon resonance (SPR) using isolated TCRs. In this case alpha and betachain sequences are expressed in E. coli as soluble TCRs, (WO2003020763;Boulter, et al., Protein Eng, 2003. 16: 707-711). Binding of the solubleTCRs to the complexes is analysed by surface plasmon resonance using aBIACORE 3000 instrument. Biotinylated peptide-HLA monomers are preparedas previously described (Example 2) and immobilized on to astreptavidin-coupled CM-5 sensor chip. All measurements are performed at25° C. in PBS buffer supplemented with 0.005% Tween at a constant flowrate. To measure affinity, serial dilutions of the soluble TCRs areflowed over the immobilized peptide-MHCs and the response values atequilibrium determined for each concentration. Data are analysed byplotting the specific equilibrium binding against protein concentrationfollowed by a least squares fit to the Langmuir binding equation,assuming a 1:1 interaction.

Results

TCRs that specifically recognise peptide-HLA complexes of the inventionwere obtained from the library. FIG. 4 shows ELISA data for three suchTCRs.

Amino acid sequences of the TCR alpha and beta variable regions of theTCRs identified in FIG. 4 are provided in FIG. 5.

These data confirm that antigen specific TCRs can be isolated.

1. A polypeptide comprising: (a) the amino acid sequence of any one ofSEQ ID NOS: 1-3, or (b) the amino acid sequence of any one of SEQ IDNOs: 1-3 with the exception of 1, 2 or 3 amino acid substitutions and/or1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions,wherein the polypeptide is capable of forming a complex with a MajorHistocompatibility Complex (MHC) molecule.
 2. The polypeptide of claim1, wherein the polypeptide consists of from 8 to 16 amino acids.
 3. Thepolypeptide of claim 1, wherein the polypeptide consists of the aminoacid sequence of any one of SEQ ID NOs 1-3.
 4. A complex of thepolypeptide of claim 1 and a Major Histocompatibility Complex (MHC)molecule.
 5. The complex of claim 4, wherein the MHC molecule is MHCclass I.
 6. A nucleic acid molecule that encodes the polypeptide asdefined in claim
 1. 7. A vector comprising the nucleic acid molecule asdefined in claim
 6. 8. A cell comprising the vector as claimed in claim7.
 9. A binding moiety capable of specifically binding the polypeptideof claim
 1. 10. The binding moiety of claim 9, capable of specificallybinding the polypeptide when it is in complex with MHC.
 11. The bindingmoiety of claim 10, wherein the binding moiety is a T cell receptor(TCR) or an antibody.
 12. The binding moiety of claim 11, wherein thebinding moiety is a TCR.
 13. A method of treating or preventing adisease in a subject in need thereof, comprising administering to thesubject a therapeutically effective amount of a binding moiety asdefined in claim
 9. 14. The method of claim 13 wherein the disease iscancer.
 15. A pharmaceutical composition comprising a binding moiety asdefined in claim 9 and a pharmaceutically acceptable carrier.
 16. Amethod of identifying a binding moiety that binds the complex as definedin claim 4, the method comprising contacting a candidate binding moietywith the complex and determining whether the candidate binding moietybinds the complex.
 17. The polypeptide of claim 2, wherein thepolypeptide consists of 9 to 13 amino acids.
 18. The complex of claim 4,wherein the complex further comprises a biotin tag.
 19. The bindingmoiety of claim 11, wherein the binding moiety is an antibody.
 20. Thebinding moiety of claim 12, wherein the TCR is on the surface of a cell.